Health plans and drug companies dip their toes into value-based pricing: The pressure is on P&T committees to monitor utilization

P and T

Volumn 41, Issue 1, 2016, Pages

  Barlas, Stephen ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; EVOLOCUMAB; HEPATITIS C VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEDIPASVIR PLUS SOFOSBUVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN PLUS SITAGLIPTIN; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; SIMEPREVIR; SITAGLIPTIN; SOFOSBUVIR;

ARTICLE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART INFARCTION; HEPATITIS C; HUMAN; PHARMACY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 84962026607     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Harvard Pilgrim Health Care. Harvard Pilgrim negotiates first-in-the nation innovative contract for blockbuster cholesterol drug Repatha. November 92015;Available at: http://www.businesswire.com/news/home/20151109006090/en/Harvard-Pilgrim-Negotiates-First-In-The-Nation-Innovative-Contract. Accessed November 21, 2015
2. Cigna. Cigna and Merck sign performance-based contract. April 232009;Available at: http://www.cigna.com/newsroom/. Accessed November 21, 2015
3. Institute for Clinical and Economic Review. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks. Draft report September 82015;Accessed November 21, 2015
4. Amgen. Amgen response to the Institute for Clinical and Economic Review (ICER) draft report on effectiveness, value, and pricing benchmarks for PCSK9 inhibitors for high cholesterol. September 282015;Available at: http://wwwext.amgen.com/~/media/amgen/full/www-amgen-com/downloads/amgen_response_to_icer_pcsk9i_report.ashx?la=en. Accessed November 21, 2015
5. Rodriguez-Gutierrez R, Shah ND, Montori VM. Predicting the overuse of PCSK-9 inhibitors. JAMA 2015, 314:1909-1910. 10.1001/jama.2015.13414
6. Aon PLC. U.S. specialty pharmacy cost increases expected to jump to 23%. August 272015;Available at: http://aon.mediaroom.com/index.php?s=25776&item=137291. Accessed November 21, 2015
7. Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015, 163: 215-223. 10.7326/M15-0406
8. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol 2013, 31:3600-3604. 10.1200/JCO.2013.49.1845